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1. Introduction  
The epidemiology of HIV infection in Spain has changed during the past decade. 
Surveillance of HIV infection occurs in 15 of the country’s 17 regions, and 2,264 new HIV 
infections were diagnosed in 2009 (Ministerio de Sanidad y Política Social, Ministerio de 
Ciencia e Innovación, 2010).  
As previously reported (Hernandez-Aguado, 1999), the HIV epidemic in Spain has been 
largely driven by injecting drug users (IDUs). Reductions in the rates of new infections 
among drug users were reported a decade ago for the first time since the beginning of the 
epidemic (Castilla, 2006). In 2009, 77.0% of new infections were acquired through sexual 
transmission, and IDUs represented less than 10% of reported cases (Ministerio de Sanidad 
y Política Social, Ministerio de Ciencia e Innovación, 2010). 
The HIV epidemic among IDUs continues to develop heterogeneously across different parts 
of Europe. In the European Union, the reported rates of newly diagnosed cases of HIV 
infection in IDUs are mostly stable or in decline (European Monitoring Centre for Drugs and 
Drug Addiction, 2009). Data on newly reported cases of HIV infection in IDUs for 2007 
suggest that rates of infection are still declining in Europe following a peak in 2002, which 
was caused by outbreaks in Estonia, Latvia and Lithuania. In 2007, the overall rate of newly 
reported infections of HIV among IDUs in the 24 EU member states for which national data 
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were available was 4.7 cases per million population, slightly lower than the 5.0 per million 
population reported in 2006. 
Non-injecting drug users are not parenterally exposed to HIV infection, but they remain at 
risk of acquiring HIV through sexual transmission. Several studies regarding risky sexual 
practices suggest an association between the abuse of cocaine, amphetamines, and alcohol 
and sexual transmission of HIV (Wang, 2010; Baliunas, 2010; Booth, 2000; de Azevedo, 2007; 
Colfax, 2010; Van Tieu, 2009). For these reasons, it is clear that drug users, independent of 
the route of administration, are a population at risk of HIV infection. Therefore, they are 
candidates for participation in studies on the efficacy of a preventive vaccine.  
In Spain in 2009, the most prevalent route of acquisition of HIV was through transmission 
among men who have sex with men (MSM)  (42.5%), followed by heterosexual transmission, 
who represented 34.5% of cases. Among men, over 50% of new HIV diagnoses are 
associated with MSM transmission. There has been a downward trend in the proportion of 
cases from heterosexual transmission (44.4% of cases in 2004 and 34.5% of cases in 2009). In 
contrast, MSM transmission accounts for a growing proportion of cases, increasing from 
28.8% in 2004 to 42.5% in 2009 (Ministerio de Sanidad y Política Social, Ministerio de Ciencia 
e Innovación, 2010). Several risk factors contribute to the sexual transmission of HIV, 
including socioeconomic status and individual factors such as having multiple sexual 
partners or unprotected sex (Staras, 2009; Hallfors, 2007; Adimora, 2006). 
The development of effective vaccines against HIV is the main focus of HIV research and 
provides hope for limiting the epidemic. In phase III clinical trials of a vaccine, the 
involvement of thousands of people and a measure of the background incidence of HIV 
infection are necessary to establish population efficacy (Celentano, 1995; Vanichseni, 2001; 
Newman, 2010b). Cohorts with less than 2  100 person-years (p-y) of HIV incidence and 
less than 90% retention are considered inappropriate for these trials partly because they 
are not likely to provide sufficient statistical power to demonstrate an effect of the 
intervention. The HIV incidence rate in a vaccine efficacy trial performed among IDUs 
from Thailand showed an HIV incidence rate of 3.4 per 100 p-y (Suntharasamai, 2009); in 
IDUs from metropolitan Barcelona, incidence is half that shown in the vaccine efficacy 
trial performed in Thailand in the same type of population (Muga, 2010). In other studies, 
the rate has varied by geographic area (Kozlov, 2006; Kellogg, 2001; Bruandet, 2006; Duan, 
2009).  
Globally, cohorts of HIV-negative individuals at high risk of HIV infection have been 
extensively studied to monitor the incidence of HIV-1 and assess their involvement in 
vaccine efficacy studies. Currently, there are three international phase III HIV vaccine 
studies (Table 1). Spain participates in an increasing number of European and North 
American initiatives to prepare for preventive HIV vaccine trials, but few studies have 
evaluated the acceptability of a preventive vaccine against HIV/AIDS among potential 
recipients and their willingness to participate in clinical trials (Etcheverry, 2011). 
Factors positively correlated with a decision to participate in a HIV vaccine trial may 
include altruism, higher education level, suspected exposure to HIV, protection against HIV 
infection, and free medical care and economic incentives (Strauss, 2001; Golub, 2005). 
Barriers to participation include little information about the vaccine trials, vaccine-induced 
seropositivity to HIV in tests, and associated stigma or discrimination (Strauss, 2001; Golub, 
2005). Given the historical underutilization of existing preventive vaccines, such as the 
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hepatitis B vaccine, among MSM (in part due to a lack of information (Jacobson, 2007; 
Schutten, 2002)), it is important to anticipate and understand the characteristics of potential 
volunteers for an HIV vaccine trial in detail.  
 
 
Trial ID Strategy Group of risk Start Date Volunteers 
RV 144 
Viral vector-
Pox/Protein 
HIV-uninfected Thai adults 10/2/2003 16,403 
VAX 003 Protein Intravenous drug users in Bangkok  3/1/1999 2,500 
VAX 004 Protein 
Adults at risk of sexually 
transmitted HIV in North America 
6/1/1998 5,400 
 
Table 1. Characteristics of current phase III clinical trials. Information was taken from the 
Database of AIDS Vaccine Candidates in Clinical Trials available at 
http://www.iavireport.org. 
The main objective of this study was to assess HIV risk behavior in drug users and sexual 
partners of HIV-infected patients and to analyze the degree of acceptance and willingness to 
participate (WTP) in HIV vaccine efficacy trials in metropolitan Barcelona. 
2. Patients and methods 
Drug addicts were recruited in two centers for substance abuse treatment located in 
Badalona, Spain (Hospital Universitari Germans Trias i Pujol and the Municipal Center for 
Substance Abuse Treatment, known as CAS Delta) between November 2007 and May 2010. 
During the same period, sexual partners of HIV-infected patients were recruited in an 
HIV/AIDS unit at the Hospital Universitari Germans Trias i Pujol.  
The three patient enrollment sites in the study were located in Badalona, north of Barcelona. 
The CAS Delta treats patients with substance abuse who live in two cities, Badalona (220,000 
inhabitants) and Santa Coloma de Gramenet (110,000 inhabitants). The Hospital Universitari 
Germans Trias i Pujol is a tertiary teaching hospital with 600 beds in Badalona; the 
HIV/AIDS Unit at Hospital Universitari Germans Trias i Pujol treated in 2010 more than 
1,500 HIV-positive patients.  
Drug users were diagnosed with drug dependence disorders according to the Diagnostic 
and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) (American Psychiatric 
Association, 2000) and had been referred for substance abuse treatment. The primary drugs 
of abuse were stimulants (cocaine) and depressants (opiates and alcohol). To be considered 
for inclusion in the study, drug users had to 1) be 18 years of age or older, 2) be actively 
using drugs, 3) have HIV-negative status at the time of inclusion, and 4) give informed 
consent. Drug users at risk of infection who met the inclusion criteria answered a 56-
question survey, which collected data on personal history (age, sex, place of origin, 
educational level, and employment status), drug use (the quantity, frequency, and treatment 
history for alcohol, cocaine, heroin, and other substances), sexual behavior (sexual 
orientation, number of partners, characteristics of the sexual partners regarding drug use 
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and paid sex, and condom use), history of sexually transmitted diseases, knowledge and 
opinions about a potential HIV vaccine, WTP, and the subject’s availability for an extended 
follow up. The survey questions were presented by doctors and nurses from both recruiting 
centers, individually and in a quiet setting with no other people present.  
To be considered for inclusion in the study, sexual partners of patients with HIV infection 
had to 1) be 18 years old or older, 2) have been a stable partner for at least 6 months, 3) be 
HIV-negative at the time of inclusion, and 4) give informed consent. Participants were given 
a shortened version of the previously described questionnaire that collected data on 
personal history, sexual behavior, and WTP. The questionnaire was given in the HIV/AIDS 
unit and was conducted by trained personnel.  
In both groups at risk for HIV infection, the degree of WTP in a potential HIV vaccine-
efficacy trial was assessed on a four-point scale questionnaire:  
a. I am definitely willing to participate [definitely yes]; 
b. I want to participate, but need to think about it [probably yes]; 
c. I do not want to participate but will think about it [probably not]; 
d. I am not at all willing to participate [definitely not]. 
The group of drug users was given an additional question related to the possibility of 
receiving remuneration for participating in a vaccine study: If you were paid, would you 
agree to volunteer in a potential HIV vaccine efficacy trial?  
After the questionnaires were completed, participants were scheduled for a blood draw to 
detect possible HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) infections. The 
blood samples were tested by enzyme immunoassay (EIA) for antibodies to HIV infection 
(Genetic Systems, Bio-Rad Laboratories, Seattle, WA or Abbot HIVAB, Abbot Laboratories, 
North Chicago, IL) and confirmed by western blot. Infection with HCV was determined by 
EIA (Ortho HCV, Ortho Diagnostics, Raritan, NJ). Blood samples were tested for the HBV 
surface antigen (Auszyme Monoclonal EIA or AxSYM microparticle enzyme immunoassay 
(MEIA), Abbott Laboratories, North Chicago, IL), anti-HBs (Ausab (EIA) or AxSYM (MEIA), 
Abbot Laboratories, North Chicago, IL), and anti-HBc (Corzyme (EIA) or AxSYM (MEIA), 
Abbot Laboratories, North Chicago, IL).   
The methods used to conduct this study met the ethical standards for medical research and 
the principles of good clinical practice.  
2.1 Statistical analysis  
Data from the two groups at risk of HIV infection were pooled. A total of 21 variables were 
common to both risk groups.  
For drug users, we developed an index that evaluated the level of risk of infection based on 
10 questions:  
1. Have you ever used drugs intravenously? 
2. Have you shared elements to inject?  
3. How many sexual partners have you had in the past year?  
4. Have you had sex for drugs? 
5. Have you ever had sex with people who were under the influence of drugs? 
6. Have you ever had sex with prostitutes? 
7. Have you ever had sex with someone infected with HIV?  
8. Have you had sex under the influence of drugs?  
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9. When you have a steady partner, do you use condoms?  
10. When you do not have a steady partner, do use condoms?  
For each of the questions, we created an indicator, 0/1, corresponding to no risk/risk. We 
then summed the indicators obtained for all ten questions. A value between 0 and 3 points 
was defined as low risk, between 4 and 6 points as moderate risk, and more than 6 points as 
high risk.  
We performed a descriptive analysis and a bivariate analysis by risk group for HIV 
infection, WTP, and other variables of interest. The outcome variable of WTP was 
dichotomized so that there were enough subjects in each category for comparison: the 
variable was “yes” if WTP was “definitely willing” or “probably willing” and “no” if the 
answer was “probably not” or “definitely not”. 
We used the chi-square test, Fisher’s F-test, and Student’s t-test when appropriate to detect 
significant differences. In addition, we calculated the odds ratio to quantify the probabilities 
of WTP. Logistic regression methods were used to determine predictive factors for 
participation in a phase III clinical trial. Variables that were statistically significant in the 
bivariate analysis were used as co-variables in the regression. Data were entered into a 
Microsoft Access 2003 database. All statistical analyses were performed using Stata software 
(version 8.0; StataCorp, College Station, TX). Values of p < 0.05 were considered statistically 
significant.  
3. Results  
A total of 232 HIV-seronegative individuals were analyzed. The median age at study entry 
was 39 years (interquartile range (IQR), 33-45 years), and 64% were men. Almost 17% of 
participants had attained at least a high school education. Seventy-nine individuals (34%) 
were drug users, and 153 (66%) were sexual partners of HIV-positive patients. Among drug 
users, 82.3% were men, the median age was 35.4 years (IQR, 29.4 - 40.0 years), most (57.7%) 
had finished elementary school, and 96.2% were heterosexual. Among the sexual partners, 
54.2% were men, the median age was 41 years (IQR, 35.6 - 46.6), 40% had completed middle 
school, and 67.5% were heterosexual. These and other results can be seen in Table 2, which 
summarizes the characteristics of the study population overall and by risk group.  
The overall prevalence of HCV was 20.5%. This prevalence was higher among drug users 
than in the other group (41.6% vs. 8.3%). Among drug users, 22.4% (11/49) had a serologic 
pattern of HBV-vaccine-induced immunity [i.e., HBsAg (-), HBsAb (+), and HBcAb (-)], and 
the serology of 7 of 49 (14.3%) users reflected immunity from natural infection. 
None of the sexual partners of the HIV-positive patients had the three serological markers of 
HBV. In the same blood sample, we confirmed that all participants were negative for HIV. 
Table 3 summarizes the HCV and HBV statuses of participants at the time of inclusion in the 
study.  
With regard to risky behaviors of drug users, it was noted that 46% (36/78) were or had 
been IDUs, and 50% admitted to having shared injecting equipment at some point. In 
addition, 45% of IDUs reported that they drank alcohol daily, 35.5% had been to jail, and 
14.7% had never used condoms despite not having had a stable sexual partner. In general, 
the level of risk of HIV infection was low for approximately 55% of drug users (43/78) and 
elevated in 7.7% (6/78). These and related findings on risky behavior among drug users are 
summarized in Table 4.  
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Drug users 
N = 79 
n (%) 
Sexual partners
 of HIV+ patients
N = 153 
n (%) 
 
Total 
N = 232 
n (%) 
Gender 
   Male 
   Female 
 
65 (82.3) 
14 (17.7) 
 
83 (54.2) 
70 (45.8) 
 
148 (63.8) 
84 (36.2) 
Age (median [IQR]) 35.4 [29.4-40.0] 41.1 [35.6-46.6] 39.3 [33.0-44.8] 
Education (n=128) 
   None    
   Primary school 
   Middle school 
   High school 
 
8 (10.3) 
45 (57.7) 
23 (29.5) 
2 (2.5) 
 
2 (1.4) 
50 (34.0) 
59 (40.1) 
36 (24.5) 
 
10 (4.4) 
95 (42.2) 
82 (36.4) 
38 (16.9) 
Last consumption of drugs (n=231) 
   Never 
   < 1 month 
   1-12 months 
   > 12 months 
 
0 (0) 
54 (69.2) 
19 (24.4) 
5 (6.4) 
 
123 (80.4) 
25 (16.3) 
2 (1.3) 
3 (2.0) 
 
123 (53.2) 
79 (34.2) 
21 (9.1) 
8 (3.5) 
Sexual behavior (n=128) 
   Homosexual 
   Heterosexual 
   Bisexual 
 
1 (1.3) 
75 (96.2) 
2 (2.6) 
 
49 (32.5) 
102 (67.5) 
0 (0.0) 
 
50 (21.8) 
177 (77.3) 
2 (0.9) 
Willingness to participate 
   No 
   Yes 
 
48 (60.7) 
31 (39.3) 
 
1 (0.7) 
152 (99.3) 
 
49 (21.1) 
183 (78.9) 
 
Table 2. Characteristics of drug users and HIV-positive sexual partners.  
 
 
 
 
Drug users 
n / N (%) 
Sexual partner 
 of HIV+ patients 
n / N (%) 
 
Total 
n / N (%) 
HCV+ 32/77 (41.6) 11/133 (8.3) 43/210 (20.5) 
HBsAg+ 0/72  (0) 1/77 (1.3) 1/149 (0.7) 
HBcAb+ 13/62 (21.0) 11/42 (26.2) 24/104 (23.1) 
HBsAb+ 19/52 (36.5) 16/42 (38.1) 35/94 (37.2) 
 
Table 3. Serological status of the study population according to risk of infection.  
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 N=79 
n (%) 
Recent (< 1 year) usage of IV drugs (n=78) 14 (17.9) 
History (> 1 year) of IV drug use (n=78) 22 (28.2) 
Have you shared injecting equipment? (n=36) 
   Yes 
   No 
 
18 (50.0) 
18 (50.0) 
Do you go to the needle-exchange locations? (n=32) 
   Yes 
   No 
 
14 (43.7) 
18 (56.3) 
Are you in a methadone program? (n=77) 
  Yes 
   No 
 
29 (37.7) 
48 (62.3) 
Have you consumed alcohol in the past year? (n=78) 
  Yes 
  No 
 
47 (60.3) 
 31 (39.7) 
Do you consume alcohol daily? (n=47) 
  Yes 
  No 
 
22 (46.8) 
25 (53.2) 
Have you required medical attention for drug use in the past year? (n=74) 
   Yes 
   No 
 
26 (35.1) 
48 (64.9) 
Have you been in prison? (n=76) 
   Yes 
   No 
 
27 (35.5) 
49 (64.5) 
How many sexual partners have you had in the past year? (n=78) 
   0 
   1-5 
   6-10 
   11-20 
   >20 
 
17 (21.8) 
55 (70.5) 
3 (3.8) 
1 (1.3) 
2 (2.6) 
Have you had sex for drugs? (n=78) 
   Yes 
   No 
   Don’t know/refused 
 
4 (5.1) 
73 (93.6) 
1 (1.3) 
 
Table 4. Risk behaviors in drug users at risk of HIV infection. 
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 N=79 
n (%) 
Have you had sex with people who were under the influence of drugs? 
(n=78) 
   Yes 
   No 
   Don’t know/refused 
 
 
51 (65.4) 
26 (33.3) 
1 (1.3) 
Have you had sex with prostitutes? (n=74) 
   Yes 
   No 
   Don’t know/refused 
 
40 (54.0) 
33 (44.6) 
1 (1.4) 
Have you had sex with someone infected with HIV? (n=78) 
   Yes 
   No 
   Don’t know/refused 
 
9 (11.5) 
60 (76.9) 
9 (11.6) 
Have you had sex while under the influence of drugs? (n=78) 
   Yes 
   No 
   Don’t know/refused 
 
68 (87.2) 
10 (12.8) 
0 (0) 
Do you currently have a steady partner? (n=78) 
   Yes 
   No 
 
34 (43.6) 
44 (56.4) 
When you have a steady partner, do you use condoms? (n=76) 
   Always 
   Sometimes 
   Never 
 
14 (18.4) 
27 (35.5) 
35 (46.1) 
When you have no steady partner, do you use condoms? (n=75) 
   Always 
   Sometimes 
   Never 
 
43 (57.3) 
21 (28.0) 
11 (14.7) 
Table 4. (Cont.). Risk behaviors in drug users at risk of HIV infection. 
Notably, nearly 30% of the stable partners of HIV-infected people did not consistently use 
condoms, and 23.2% acknowledged having had sex under the influence of drugs. Table 5 
summarizes risk behaviors in this population.  
Overall, 47.4% of participants answered that they would definitely be willing to participate 
in HIV vaccine efficacy trials, 31.5% were probably willing, 9.1% wrote they were probably 
not willing, and 12.1% indicated they were definitely not willing to join vaccine trials. 
Among drug addicts, 13.9% were definitely willing to participate, in contrast to 64.7% of 
sexual partners of HIV-infected patients (p<0.05). Figure 1 shows the characteristics of WTP 
according to both study populations. Among drug users, it should be noted that only one 
person indicated a shift in WTP from “probably no” to “probably yes” if the study were to 
involve remuneration. 
www.intechopen.com
Acceptability of HIV Vaccine - Efficacy Trials in Drug Users  
and Sexual Partners of HIV Infected Patients in Barcelona, Spain 
 
329 
 N=153 
n (%) 
Have you used drugs in the past month? 
   Yes 
   No 
 
30 (19.6) 
123 (80.4) 
Do you have a history of IV drug use? 3 (2.0) 
Have you had sex with people under the influence of drugs? (n=56) 
   Yes 
   No 
   Don’t know/refused 
 
13 (23.2) 
42 (75.0) 
1 (1.8) 
Have you had sex with prostitutes? (n=67) 
   Yes 
   No 
   Don’t know/refused 
 
14 (20.9) 
52 (77.6) 
1 (1.5) 
Have you had sex while under the influence of drugs? (n=150) 
   Yes 
   No 
 
16 (10.7) 
134 (89.3) 
When you have a steady partner, do you use condoms? (n=146) 
   Always 
   Sometimes 
   Never 
 
104 (71.2) 
29 (19.9) 
13 (8.9) 
Table 5. Sexual risk behaviors of sexual partners of HIV-infected patients.  
 
35,4
25,3 25,3
13,9
0 0,7
34,6
64,7
0
10
20
30
40
50
60
70
Definitely not Probably not Probably yes Definitely yes
%
Drug users Sexual partners of HIV-positive patients
 
 
Fig. 1. Willingness to participate in HIV vaccine efficacy trials among drug addicts and 
sexual partners of HIV-positive patients in Badalona, Spain. 
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Table 6 summarizes WTP in both risk groups. This table shows that WTP in drug users is 
more common in women, in those with elementary-school education, in those who have 
recently used drugs, and in those who show a high number of risk behaviors. In sexual 
partners of HIV-positive patients, the vast majority (>95%) would be willing to participate 
in a clinical trial.  
 
 Willingness to participate 
 Drug users 
N=79 
Sexual partners of HIV-
positive patients 
N=153 
 n (%) p-value n (%) p-value 
Gender 
   Male 
   Female 
 
22 (33.8) 
9 (64.3) 
 
0.034 
 
83 (100.0) 
69 (98.6) 
 
0.458* 
Age (mean  SD) 34.9 9.5 0.944 41.6  8.3 0.872 
Education (n=128) 
   None    
   Elementary school 
   Middle  
   High 
 
3 (37.5) 
19 (42.2) 
8 (34.8) 
0 (0) 
 
0.647 
 
2 (100.0) 
50 (100.0) 
58 (98.3) 
36 (100.0) 
 
1.000* 
Last consumption of drugs (n=231) 
   Never 
   < 1 month 
   1-12 months 
   > 12 months 
 
-- 
23 (42.6) 
7 (36.8) 
1 (20.0) 
 
0.588 
 
122 (99.2) 
25 (100.0) 
2 (100.0) 
3 (100.0) 
 
1.000* 
Sexual behavior (n=128) 
   Homosexual 
   Heterosexual 
   Bisexual 
 
1 (100.0) 
28 (37.3) 
2 (100.0) 
 
0.059* 
 
101 (99.0) 
49 (100.0) 
-- 
 
1.000* 
Risk behavior 
   Low 
   Moderate 
   High 
 
10 (23.8) 
16 (55.3) 
5 (83.3) 
 
0.003 
  
* F-test  
Table 6. Willingness to participate in HIV vaccine trials among drug users and sexual 
partners of HIV-positive patients.  
There were also significant differences between drug users by gender. The probability that a 
female drug user agreed to participate in a future vaccine trial for HIV was more than three 
times higher than in men (OR = 3.52, 95% CI: 1.05-11.77). Having a moderate or high risk of 
HIV infection (> 3 points) was also associated with WTP (OR = 4.48, 95% CI: 1.70-11.83). 
Figure 2 shows WTP according to the level of risk of HIV infection in drug users.  
In the multivariate analysis, being female (OR = 5.6, 95% CI: 1.4-22.4) and having a 
moderate-to-high level of infection risk (OR = 6.6, 95% CI: 2.2-19.6) were predictors of 
participation in a phase III vaccine trial among drug users.  
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Fig. 2. Willingness to participate according to the level of risk of HIV infection in drug users. 
4. Conclusion 
Understanding the candidate population of volunteers is crucial for analyzing the efficacy of 
a potential preventive vaccine trial. In Spain, drug users have exhibited an elevated risk of 
HIV infection. In anticipation of a safe and effective vaccine candidate, it is appropriate to 
assess potential sites and populations for future vaccine trials. Accordingly, this study was 
developed to analyze WTP in a hypothetical HIV vaccine efficacy trial among current drug 
users in an urban area, many of whom have been affected by HIV/AIDS and parenteral 
drug addiction for many years. Sexual partners of HIV-infected patients are, by definition, 
another population at risk and therefore also potential trial participants. 
In this study, we observed that WTP is clearly higher in sexual partners of HIV-positive 
patients and falls far short of 40% in potentially eligible drug users. To the best of our 
knowledge, this is the first study to report WTP in HIV vaccine trials in sexual partners of 
HIV patients in Spain. A high rate of acceptability of an HIV vaccine trial in this risk group 
has not been reported in other countries, although one study has demonstrated WTP in an 
overwhelming majority of monogamous married women (Suhadev, 2006). A predisposition 
toward WTP is already known among homosexuals (Newman, 2010b; Li, 2010) and, more 
particularly, in those who report family support for participation and expect that the vaccine 
will protect them against HIV infection (Li, 2010).  
The WTP of drug users in this study was lower than that of other studies conducted in our 
area and in other areas. For example, a study recently conducted in our area on 326 drug 
users found WTP in 83% of cases (51% would definitely participate, and 32% would 
probably participate) (Etcheverry, 2011). In China, a study conducted among 401 IDUs 
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showed a rate of definite WTP of approximately 75%; the rate reached 94% if the group that 
indicated a probable WTP was included (Yin, 2008). 
One of the findings among drug users is noteworthy: those who showed an increased risk of 
infection were the most likely to agree to participate in a phase III vaccine trial. A recent 
meta-analysis of HIV vaccine acceptability indicated a significant impact of self-
identification as a member of a risk group and perceived susceptibility to HIV infection on 
HIV vaccine acceptability, thus suggesting potentially modifiable factors beyond vaccine 
characteristics that may influence uptake (Newman, 2010a). This finding may explain the 
high rate of WTP in this subgroup of drug users compared to the mean of this population 
(83.3% vs. 39.2%).  
Among active drug users, women showed greater willingness to participate in a phase III 
vaccine trial. Greater availability and motivation of women has also been noted in other 
studies, although in different risk groups (Aliyu, 2010; Colfax, 2005). 
The rate of HIV incidence among IDUs in our area is half that found in a similar population 
in Thailand (Suntharasamai, 2009; Muga, 2010). In the study by Muga et al., the proportion 
of IDUs admitted for substance abuse treatment had decreased considerably in recent years 
(Muga, 2010). When combined with the relatively low incidence of HIV infection in recently 
recruited IDUs, these data suggest that drug users may not be included in future studies on 
preventive HIV/AIDS vaccine efficacy trials.  
The results from this study indicate that the prevalence of HCV in drug users and in sexual 
partners of HIV-positive patients is relatively high (41.6% and 8.3%, respectively). These 
results suggest the possibility that some of the individuals in the drug users group who self-
reported as non-IDUs may have injected drugs in the past. However, the risk of sexual 
transmission of an HCV infection is associated with a history of multiple sexual partners 
and a lack of condom usage (Alter, 1990; Osmond, 1993; Rauch, 2005). Thus, the high 
prevalence of HCV infection in both risk groups in this study could be explained by the 
large number of subjects who said that they never use condoms. It was also noted that over 
20% of drug users had been vaccinated for HBV. Although the percentage of people 
vaccinated against HBV is low globally, these results are consistent with others noting that 
vaccine-induced immunity to HBV infection in Spain has been increasing (Rivas, 2010). 
Several limitations of this study should be mentioned. First, the survey did not include 
issues related to vaccine trial attributes, such as vaccine-induced infection, side effects, or 
false-positives on HIV tests, which are associated with lower WTP (Mills, 2004). Thus, the 
results of this study may overestimate WTP. In addition, self-reported data on risk 
behaviors related to drug use and sexual behavior could overestimate current risk 
behaviors. This study has a cross-sectional design and therefore cannot analyze changes in 
the WTP that might be seen following retention strategies and vaccine education.  
This is the first study in Spain to evaluate WTP among sexual partners of HIV-positive 
patients. The number of people at risk who participated is high, and the study environment 
is appropriate because the involved facilities have the ability to implement phase I or II 
vaccine trials.  
In the case of a phase III preventive vaccine trial in Spain, it could become necessary to 
recruit a large number of people at risk of infection. The stated WTP in hypothetical HIV 
vaccine trials was high among sexual partners of HIV-positive patients. Specific 
interventions are needed to increase the acceptability of vaccine trial participation among 
drug users at risk of HIV infection.  
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